BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31980993)

  • 1. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
    Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
    AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
    Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
    Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
    Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM;
    AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
    Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
    AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
    Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
    AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.
    Garcia M; Luecke E; Mayo AJ; Scheckter R; Ndase P; Kiweewa FM; Kemigisha D; Musara P; Mansoor LE; Singh N; Woeber K; Morar NS; Jeenarain N; Gaffoor Z; Gondwe DK; Makala Y; Fleurs L; Reddy K; Palanee-Phillips T; Baeten JM; van der Straten A; Soto-Torres L; Torjesen K
    BMC Public Health; 2021 Nov; 21(1):2041. PubMed ID: 34749675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
    Laborde ND; Pleasants E; Reddy K; Atujuna M; Nakyanzi T; Chitukuta M; Naidoo S; Palanee-Phillips T; Baeten JM; Montgomery ET;
    AIDS Behav; 2018 Feb; 22(2):437-446. PubMed ID: 29151197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
    Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
    AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence.
    Stoner MCD; Brown ER; Palanee-Phillips T; Mansoor LE; Tembo T; Nair G; Akello C; Seyama L; Jeenarain N; Naidoo L; Mgodi N; Hunidzarira P; Chitukuta M; van der Straten A;
    AIDS Behav; 2021 Dec; 25(12):4169-4179. PubMed ID: 33939034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
    Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
    PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
    Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
    AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
    Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
    Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
    AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex.
    Browne EN; Torjesen K; Mirembe BG; Palanee-Phillips T; Jeenarain N; Chitukuta M; Stoner MCD; Mansoor LE; Reddy K; Tauya TT; Naidoo L; Siva S; Richardson B; Dadabhai S; Seyama L; Soto-Torres L; van der Straten A;
    AIDS Care; 2024 Jan; 36(1):80-86. PubMed ID: 37066990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
    Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
    BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention.
    Reddy K; Mathebula F; Katz A; Luecke E; Tenza S; Palanee-Phillips T; Garcia M; Mansoor LE; Naidoo S; Morar N; Chitukuta M; Tsidya M; Montgomery ET;
    AIDS Behav; 2022 Jun; 26(6):1923-1932. PubMed ID: 35064389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
    Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
    J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.
    Browne EN; Brown ER; Palanee-Phillips T; Reddy K; Naidoo L; Jeenarain N; Nair G; Husnik MJ; Singh D; Scheckter R; Soto-Torres L; Baeten JM; van der Straten A;
    J Acquir Immune Defic Syndr; 2022 Aug; 90(4):418-424. PubMed ID: 35344520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring.
    van der Straten A; Browne EN; Shapley-Quinn MK; Brown ER; Reddy K; Scheckter R; Soto-Torres L; Palanee-Phillips T; Baeten JM; Mensch B;
    J Acquir Immune Defic Syndr; 2019 Jul; 81(3):304-310. PubMed ID: 30844995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
    Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
    AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.